文献速递间质性肺疾病

吡非尼酮抑制MRTF活化:临床可实现的抗纤维化机制

Inhibition of MRTF activation as a clinically achievable anti-fibrotic mechanism for pirfenidone.
PubMed 文献 · Eur Respir J · 2023-04-27

该研究通过转录组和免疫荧光分析原代人IPF组织,发现IPF肺肌成纤维细胞中MRTF信号激活,吡非尼酮在临床可达浓度下抑制原代人肺成纤维细胞MRTF活化,且治疗后的IPF肺成纤维细胞灶MRTF活化显著减少,提示MRTF信号是吡非尼酮的直接靶点。

要点

  • IPF肺肌成纤维细胞中MRTF信号激活。
  • 吡非尼酮在临床可达浓度抑制肺成纤维细胞MRTF活化。
  • 吡非尼酮抗纤维化部分源于抑制MRTF。

核心结论

  • MRTF信号是吡非尼酮的直接靶点,其抗纤维化作用部分源于抑制肺成纤维细胞MRTF活化。

研究设计与样本

  • 研究对原代人IPF组织进行转录组和免疫荧光分析。

主要发现

  • IPF肺中积聚的肌成纤维细胞MRTF信号激活。
  • 吡非尼酮抑制原代人肺成纤维细胞MRTF活化,半数抑制浓度50-150 µM,最大抑制>90%,患者最大浓度<100 µM。
  • 吡非尼酮可能通过间接促进MRTF与肌动蛋白相互作用发挥抑制作用。
  • 吡非尼酮治疗的IPF肺成纤维细胞灶MRTF活化显著少于未经治疗的IPF肺。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic disease characterised by aberrant fibroblast/myofibroblast accumulation and excessive collagen matrix deposition in the alveolar areas of lungs. As the first approved IPF medication, pirfenidone (PFD) significantly decelerates lung function decline while its underlying anti-fibrotic mechanism remains elusive. METHODS: We performed transcriptomic and immunofluorescence analyses of primary human IPF tissues. RESULTS: We showed that myocardin-related transcription factor (MRTF) signalling is activated in myofibroblasts accumulated in IPF lungs. Furthermore, we showed that PFD inhibits MRTF activation in primary human lung fibroblasts at clinically achievable concentrations (half-maximal inhibitory concentration 50-150 µM, maximal inhibition >90%, maximal concentration of PFD in patients <100 µM). Mechanistically, PFD appears to exert its inhibitory effects by promoting the interaction between MRTF and actin indirectly. Finally, PFD-treated IPF lungs exhibit significantly less MRTF activation in fibroblast foci areas than naïve IPF lungs. CONCLUSIONS: Our results suggest MRTF signalling as a direct target for PFD and implicate that some of the anti-fibrotic effects of PFD may be due to MRTF inhibition in lung fibroblasts.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Ma HY, Vander Heiden JA, Uttarwar S, et al. Inhibition of MRTF activation as a clinically achievable anti-fibrotic mechanism for pirfenidone. Eur Respir J. 2023. PMID: 36585256. doi:10.1183/13993003.00604-2022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。